(Q38612982)

4 September 2017

title

Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions (English)

1 reference

4 September 2017

1 reference

1 reference

3

Eric J Small

1 reference

4 September 2017

Xiao X Wei

1

1 reference

4 September 2017

Lawrence Fong

series ordinal

2

1 reference

4 September 2017

publication date

21 October 2015

1 reference

Expert Review of Vaccines

4 September 2017

published in

1 reference

4 September 2017

volume

14

1 reference

4 September 2017

issue

12

1 reference

4 September 2017

page(s)

1529-1541

1 reference

4 September 2017

cites work

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

The androgen axis in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Abiraterone in metastatic prostate cancer without previous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Enzalutamide in metastatic prostate cancer before chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

The immune contexture in human tumours: impact on clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

ICAM-1 signaling in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Specific stimulation of MHC-transgenic mouse T-cell hybridomas with xenogeneic APC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Immunologic correlates of the abscopal effect in a patient with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

S100A9 interaction with TLR4 promotes tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Listening to Provenge--what a costly cancer treatment says about future Medicare policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

Current vaccination strategies for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.1099437

10.1586/14760584.2015.1099437

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference